438 Studies Now Enrolling
A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 2 dose regimens of orally administered SENS-111 (100 mg and 200 mg) given during 4 days in patients suffering from Acute Unilateral Vestibulopathy
A Study To Assess The Efficacy And Safety Of 2 Dose Regimens Or Orally Administered SENS-111
| Sponsor: | Sensorion |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAR3704 |
| U.S. Govt. ID: | NCT03110458 |
| Contact: | Jessica Campbell: 212-305-2298 / jc4353@cumc.columbia.edu |
Additional Study Information:
Acute unilateral vestibulopathy (AUV) (previously called acute vestibular neuritis) is the third most frequent cause of peripheral vestibular vertigo, after benign paroxysmal positional vertigo and Menires disease.The goal of this study is to look at the effects of a new drug (SENS-111) in controlling the acute vertigo and other symptoms related to AUV more rapidly and in limiting the long-term residual symptoms.
This study is closed
